Universal Corporation (NYSE:UVV) Q3 2023 Earnings Call Transcript

Universal Corporation (NYSE:UVV) Q3 2023 Earnings Call Transcript February 8, 2023

Operator: Good afternoon. Thank you for attending today’s Universal Corporation Third Quarter Fiscal Year 2023 Earnings Call. My name is Meghan, and I’ll be your moderator for today’s call. I would now like to pass the conference over to Candace Formacek, Vice President and Treasurer. Candace, please go ahead.

Candace Formacek: Thank you, Meghan, and thank you all for joining us today. George Freeman, our Chairman, President and CEO; Airton Hentschke, our Chief Operating Officer; and Johan Kroner, our Chief Financial Officer, are here with me today and will join me in answering questions after these brief remarks. This call is being webcast live and will be available on our website and on telephone taped replay. It will remain on our website through May 8, 2023. Other than a replay, we have not authorized and disclaim responsibility for any recording, replay or distribution of any transcription of this call. This call is copyrighted and may not be used without our permission. Before I begin to discuss our results, I caution you that we will be making forward-looking statements that are based on our current knowledge and some assumptions about the future and are representative as of today only.

Actual results could differ materially from projected or estimated results, and we assume no obligation to update any forward-looking statements. For information on some of the factors that can affect our estimates, I urge you to read our 10-K for the year ended March 31, 2022, as well as our Form 10-Q for the quarter ended December 31, 2022. Such risks and uncertainties include, but are not limited to, the ongoing COVID-19 pandemic, customer-mandated timing of shipments, weather conditions, political and economic environment, government regulation and taxation, changes in exchange rates and interest rates, industry consolidation and evolution and changes in market structure or resources. Finally, some of the information I have for you today is based on unaudited allocations and is subject to reclassification.

In an effort to provide useful information to investors, our comments today may include non-GAAP financial measures. For details on these measures, including reconciliations to the most comparable GAAP measures, please refer to our current earnings press release. We are extremely pleased with our results driven by strong tobacco shipments in the nine months and quarter ended December 31, 2022, compared to the same periods in fiscal year 2022. Tobacco shipments are generally moving smoothly, and we are not seeing logistical constraints that we saw in the prior fiscal year. Our Ingredients Operations segment also continued to positively contribute to and diversify our results in the nine months and quarter ended December 31, 2022. There continues to be significant demand for leaf tobacco with all types of leaf tobacco currently in an undersupplied position.

Short burley tobacco crops in Africa, largely due to weather conditions have contributed to the lower leaf tobacco supply. As of December 31, 2022, our uncommitted inventory levels stood at less than 7% of our tobacco inventory, an exceptionally low level. Although it is still early, we are forecasting larger crops in several key tobacco origins in fiscal year 2024. In our Ingredients Operations segment, we recently have been experiencing some softening of demand for some of our ingredients products, which we believe is temporary and largely due to customers adjusting their inventory levels. Some of our ingredients customers have been carrying higher inventory levels because of supply chain uncertainties. Increased costs, particularly selling, general and administrative expenses, including costs related to the expansion of sales and product development resources and deferred compensation costs from acquisitions reduced our results for our Ingredients Operations segment in the quarter and 9 months ended December 31, 2022.

We remain excited about the long-term outlook for our ingredients businesses and continue to make significant capital investments to enhance and increase the capabilities of our plant-based ingredients platform. We are ahead of achieving some of the earlier identified operational synergies across the platform and making considerable progress on our vision for this segment. As announced on February 1, 2023, we have appointed a new director with extensive experience in the ingredients and value-added supplier space to our corporate Board of Directors to assist us as we continue to promote and expand this business. Turning to the results. Net income for the nine months ended December 31, 2022, was $70.3 million or $2.82 per diluted share compared with $60.8 million or $2.44 per diluted share for the nine months ended December 31, 2021.

Excluding certain nonrecurring items detailed in today’s earnings release, net income and diluted earnings per share increased by $1.1 million and $0.04, respectively, for the nine months ended December 31, 2022, compared to the nine months ended December 31, 2021. Adjusted operating income, also detailed in today’s earnings release, of $128.7 million increased by $12.2 million for the nine months ended December 31, 2022, compared to adjusted operating income of $116.5 million for the nine months ended December 31, 2021. Net income for the quarter ended December 31, 2022, was $41.7 million or $1.67 per diluted share compared with $34.9 million or $1.40 per diluted share for the quarter ended December 31, 2021. Excluding certain nonrecurring items detailed in today’s earnings release, net income and diluted earnings per share decreased by $3.1 million and $0.13, respectively, for the quarter ended December 31, 2022, compared to the quarter ended December 31, 2021.

Photo by Louis Hansel on Unsplash

Adjusted operating income, also detailed in today’s earnings release, of $77.5 million increased by $2.7 million for the third quarter of fiscal year 2023 compared to adjusted operating income of $74.9 million for the third quarter of fiscal year 2022. Consolidated revenues increased by $419.2 million to $1.9 billion for the nine months ended December 31, 2022, compared to the same period in fiscal year 2022, on higher tobacco sales volumes and prices, as well as the addition of the business acquired in October 2021 in the Ingredients Operations segment. For the quarter ended December 31, 2022, consolidated revenues were $795 million, an increase of $142.4 million compared to $652.6 million for the quarter ended December 31, 2021, on higher tobacco sales volumes and prices.

Turning to the segment detail. Tobacco Operations. Operating income for the Tobacco Operations segment increased by $13.4 million to $119 million and by $7.3 million to $77.1 million, respectively, for the nine months and quarter ended December 31, 2022, compared to the same periods in the prior fiscal year. Tobacco Operations segment results improved primarily due to large shipments of both carryover and current crop tobacco. While sales volumes were higher in the Tobacco Operations segment in the nine months and quarter ended December 31, 2022, compared to the same periods in the prior fiscal year, margins were lower due to sales mix and sales of tobaccos that were written down in prior quarters. Tobacco shipments from Brazil of both carryover and current crops were up significantly in the nine months and quarter ended December 31, 2022, compared to the same periods in the previous fiscal year.

In Africa, despite some lower burley tobacco crop sizes, Tobacco sales volumes were up due to earlier shipment timing in the nine months and quarter ended December 31, 2022, compared to the same periods in fiscal year 2022. Results for our oriental tobacco joint venture were down in the nine months and quarter ended December 31, 2022, compared to the same periods in the prior fiscal year, on lower sales volumes and unfavorable foreign currency comparisons. Selling, general and administrative expenses for the Tobacco Operations segment were higher in the nine months ended December 31, 2022, compared to the nine months ended December 31, 2021, primarily due to unfavorable foreign currency comparisons, higher provisions to suppliers and higher compensation costs.

For the quarter ended December 31, 2022, selling, general and administrative expenses for the Tobacco Operations segment were higher compared to the quarter ended December 31, 2021, largely due to higher compensation costs and larger provisions to suppliers in part due to lower crop yields, partially offset by favorable foreign exchange comparisons. Moving to the Ingredients Operations. Operating income for the Ingredients Operations segment was $9.9 million for the nine months ended December 31, 2022, compared to $10.6 million for the nine months ended December 31, 2021, as benefits from increased sales, better margins and the inclusion of the October 2021 purchase of Shank’s Extract, LLC were offset by increased costs, mainly higher selling, general and administrative expenses.

Operating income for the segment was $0.8 million for the quarter ended December 31, 2022, compared to $3.5 million for the quarter ended December 31, 2021, on lower sales, particularly lower sales of extracts and higher costs. Selling, general and administrative expenses for the segment increased in the nine months and quarter ended December 31, 2022, compared to the same periods in the prior fiscal year, largely on higher compensation costs including final deferred compensation costs from acquisitions as well as costs related to the expansion of sales and product development capabilities of our plant-based ingredients platform. In Other Items, we successfully refinanced and expanded our bank credit facility in the quarter ended December 31, 2022, positioning us to meet our future financial needs.

In line with our previous expectations, we also reduced our outstanding borrowings considerably in the three months ended December 31, 2022, as we moved beyond our peak working capital requirements for fiscal year 2023. Also, our fiscal year 2022 Sustainability Report was published in December 2022 and is available on our website, www.universalcorp.com. Sustainability is an essential pillar of our business at Universal. We are committed to disclosing our operational activities as well as our sustainability performance in a consistent and transparent manner. We are excited about our sustainability achievements and the new and updated information and disclosures contained in our 2022 Sustainability Report. At this time, we’re available to take your questions.

Meghan, I’ll turn it back to you.

See also 11 Best American Oil Stocks To Buy and 15 Mormon Owned Companies and Stocks.

Q&A Session

Operator: Thank you. Our first question comes from the line of Ann Gurkin with Davenport & Company.

Ann Gurkin: I want to start with the ingredients segment and the slowdown in sales. And I think Candace, you just said it was mainly due to extracts, but I wanted to walk through the different segments and see if anything else is going on. Begin with FruitSmart. Is there any kind of slowdown in the end market for the use of those derivatives and beverages?

Johan Kroner: No. Ann, really where we’re seeing — it is Johan. Where we’re seeing it really is because the uncertainty there in COVID and everything, a bunch of customers just have additional inventory that they’re just trying to sell off right now, and that’s where the slowdown is, and we believe it’s temporary.

Ann Gurkin: Okay. Because it seems to me the end market for specialty ingredients is very strong, growing strong double digits. So, is that — are you also seeing reduced inventory there? I thought the pull-through from that segment was very strong.

Johan Kroner: Again, depending on what products you’re talking about, you’re partially right but in all products, it’s down a little bit. But again, we truly believe that it’s temporary at this point in time. We saw it through the quarter, there’s a bit of an uptick, but we just have to see what the rest of the quarter will do and the rest of the year.

Ann Gurkin: Okay. How do I think about fiscal ’24 for the Ingredients business?

Johan Kroner: That remains to be seen. But it looks really positive. We’re doing — we’re making some significant investments, we received quite a bit of upside. So, we’re really excited about that, but we’re incurring some additional costs as well in order to get that all up to speed. So, it looks good. Margins are holding up nicely. We just have to see what the sales do throughout the year.

Ann Gurkin: Okay. And then, in terms of SG&A, for the whole company, I never know how to think about that. It was about $70 million, slightly under that in this quarter. Do I take that and run that into fiscal ’24, or how — some of that seemed to have some of these compensation expenses and maybe Shank’s payments and different factors that maybe should flow out. I don’t know how do I think about that number for fiscal ’24?

Johan Kroner: Well, as always, there’s lots of variables in there. Exchange rates, comp costs are certainly up, inflationary things that are going on. So, at the moment, we’re in the ballpark. We’re always looking for efficiencies and things we can do. But on the other hand, again, like I said before, only ingredients side, we’re ramping up some hiring and everything. So that will increase in the amount of it. But right now, where we’re at, looks about

Candace Formacek: Ann? Are you

George Freeman: Did we lose you, Ann?

Candace Formacek: Meghan?

Operator: It does seem that Ann has muted her line?

Candace Formacek: Unmute, Ann.

Operator: Ms. Gurkin, can you hear us?

Candace Formacek: Is there another question, Meghan? Maybe we can move along if she can get back in or dial back in, we can take an extra moment for her. If you have someone else, we can…

Operator: There are no further questions registered. Okay. Our next question comes from the line of Chris Reynolds with Neuberger Berman.

Chris Reynolds: Good afternoon. Congratulations on the good quarter. I wanted to ask you just a general question about global tobacco consumption. And it seems like it continues to be pressured because of trends towards smoking less and then combustibles and then sort of general economic conditions being weak. That doesn’t appear to be showing up in your numbers though. And I’m just wondering if you can give some commentary about sort of how you view the tobacco segment. You’ve always been fairly conservative with your guidance for growth, but maybe if you could just give an update on how you view global industry consumption trends this year?

Airton Hentschke: Yes. Chris, it’s different from market to market, of course. I mean, if you separate the U.S. and the Americas, of course, Europe and Asia. We see different dynamics in different markets. But overall, we still see a very positive consumption out there, which our major customers reported numbers. And we’re very positive about the combustible side. At the same time, as we all know, there are new products in these new generation products, whether it’s heat-not-burn and vaping products out there, but we remain positive about the consumption of combustible cigarettes.

Operator: Our next question comes from the line of Bruce Monrad with Northeast Investors.

Bruce Monrad: A question, you made a reference in I think the script that there were some indications of crops for fiscal year ’24, were looking favorable. Can you add a little color on that? And then, maybe step on to that, what that might mean in terms of pricing? And I guess I’m also asking what that would mean for your inventory levels going forward and sort of on a comparison basis because I think maybe part of the reason inventories are elevated is pricing. So what’s the crop outlook or if there’s any color to add on that and how does that fit in, please?

Airton Hentschke: Certainly, Bruce. What we are seeing in the key markets, especially where we operate, we see increased crop sizes there. And that’s positive because we play an important role in these key markets as well where we promote tobacco production with our pharma base out there. What we have seen in terms of cost, of course, these inflationary costs and fertilizer costs from — that hitting this crop, we do see increase on tobacco prices, in prices to the farmer. And that is different, again, in every market. So — but we remain very positive about the demand, as you have seen there. Our uncommitted inventory is in our lowest level for many, many years. It’s about below 7% right now. We like to have some additional uncommitted inventory because we don’t want to lose any opportunity or any request that our customers have there.

So looking into this 2023 crop cycle, we remain positive. In some areas, the crop sizes are confirmed. In some other areas, they’re still developing, like Africa and some other areas, they have not been even started the growing process, so. But we remain positive about the increased crop sizes and so Universal is well positioned for that as well.